OncXerna Therapeutics

OncXerna Therapeutics, Inc. was founded in 2018 in Waltham, US, and offers therapies to improve cancer treatment.   OncXerna Therapeutics, Inc. engages in the development of therapeutic solutions primarily focused on advancing cancer treatment.

Their core products are designed to target specific cancer pathways. These therapeutics are aimed at addressing medical needs in oncology, particularly in areas such as precision medicine, where treatment is tailored based on individual patient profiles. OncXerna’s offerings are intended for use in clinical settings, targeting oncologists and healthcare institutions that serve cancer patients. The company has a strategic focus on key markets in North America and Europe, where the demand for advanced cancer therapies continues to grow.

OncXerna Therapeutics generates revenue through a combination of B2B transactions and partnerships with healthcare providers and research institutions. Their revenue model includes licensing agreements and collaborations that enable them to leverage their research and development capabilities while gaining access to broader market channels. The company’s main revenue stream is derived from the sale of its flagship therapeutics, which are marketed to hospitals and specialty pharmacies. Additionally, OncXerna is exploring further revenue opportunities through strategic alliances and partnerships that enhance its product offerings and market reach.

OncXerna Therapeutics is actively working on several new products aimed at improving cancer treatment, with plans for launches slated for the next fiscal year. The company aims to expand its market presence in North America and Europe by targeting additional regions with a projected completion date by 2025. Recent funding will be utilized to support these product launches and geographical expansions, enabling OncXerna to enhance its operational capabilities and reach a wider patient population.